Oricell Therapeutics Secures $110M for CAR-T Expansion
SHANGHAI, China, April 10, 2026 Oricell Therapeutics Holdings Limited has successfully closed a $110 million pre-IPO financing round, marking...
solid tumors
Advertisement
IDEAYA Biosciences Doses First Patient in IDE574 Trial
South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...
Blood Test Tracks Immunotherapy Response in Solid Tumors
FOSTER CITY, Calif., March 3, 2026 Adela, Inc. has announced the publication of new clinical validation data in npj...
FDA Clears IND for CS2009 Trispecific Antibody Trial
SUZHOU, China, Feb. 15, 2026 — CStone Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Investigational...
FDA Clears PRD-101 Nano Cancer Drug for Phase 1
SEONGNAM, South Korea, Feb. 6, 2026 — PharmaResearch Co., Ltd. announced that the U.S. Food and Drug Administration (FDA)...
Advertisements
Janux and BMS Partner on Tumor-Activated Cancer Therapy
SAN DIEGO, January 22, 2026 — Janux Therapeutics announced a collaboration and exclusive worldwide license agreement with Bristol Myers...
FDA Clears Allogeneic CAR-T MT027 for Phase II Glioblastoma
December 21, 2025 | Beijing, China — T-MAXIMUM Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has...
PRAME Cell Therapy Shows Strong Early Responses in Phase 1 Study
HOUSTON, Texas & TÜBINGEN, Germany — December 11, 2025 — Immatics N.V. announced compelling Phase 1a dose-escalation data for...
Rondo Therapeutics Begins Phase I Trial of RNDO-564 in Advanced Tumors
Dateline – San Francisco, CA – December 2025: Rondo Therapeutics has dosed the first patient in its Phase I...
Verismo Therapeutics Unveils Promising CAR T Advances for Solid Tumors at SITC 2025
Philadelphia, November 10, 2025 — Verismo Therapeutics, a clinical-stage biotechnology company pioneering KIR-CAR T cell therapies, presented compelling preclinical...
Advertisement
